Radioimmunotherapy with monoclonal antibodies. A new horizon in nuclear medicine therapy?
Radioimmunotherapy (RIT) with labeled tumor-associated monoclonal antibodies (MAbs) is a promising concept in oncology, which essentially consists of biological targeting of ionising radiation to tumors. Some encouraging clinical results have been achieved with RIT. However, there are severe problems associated with both understanding the mechanisms and predicting the effectiveness of RIT. This paper reviews the results of some major clinical trials, especially in malignant lymphomas and in some solid tumors. Furthermore, problems with RIT are described such as the significance of dose inhomogeneity and dose-rate effects, the appropriate dose calculation method, the toxicity of RIT and the development of HAMAs. It is suggested that newer technologies including chimeric antibodies, multiple-step targeting protocols, bone marrow transplantation, parallel application of external radiation, heat or bioreductive drugs will enable RIT to make an essential contribution to strategies for combating cancer.
Dept. of Radiooncology and Nuclear Medicine, Klinikum Karlsruhe, Katharinenhospital, Stuttgart, FRG.
M L
ML
Sautter-Bihl
H
H
Bihl
D000818:Animals; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006358:Hot Temperature / Q000627:therapeutic use; D006801:Humans; D008223:Lymphoma / Q000532:radiotherapy; D051379:Mice; D009369:Neoplasms / Q000532:radiotherapy* / Q000628:therapy; D016499:Radioimmunotherapy; D011993:Recombinant Fusion Proteins
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D011993:Recombinant Fusion Proteins